Milk Specialties Global is launching a brown rice protein called PROriz.
Photo © iStockphoto.com
Milk Specialties Global (Eden Prairie, MN) is launching a brown rice protein called PROriz. The protein is sourced and produced in the U.S. using hexane-free processing. The result is a product that contains 80% protein, and all nine essential amino acids in a low grit, neutral tasting, and free-flowing powder.
“Milk Specialties continuously looks for ways to bring protein innovation and leadership to help our customers succeed in a competitive market,” said Michael Hiron, vice president of sales, in a press release. “The demand for vegan protein is explosive, and brown rice protein brings an unparalleled solution for our customers to meet the nutritional and sensory demands of the performance nutrition consumer. PROriz is both sourced and produced the U.S.A., which is a clear differentiator to other brown rice proteins in the market.”
PROriz is available in both conventional and organic formats.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.